These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9292533)

  • 1. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells.
    Teoh G; Urashima M; Ogata A; Chauhan D; DeCaprio JA; Treon SP; Schlossman RL; Anderson KC
    Blood; 1997 Sep; 90(5):1982-92. PubMed ID: 9292533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
    Zhang Z; Li M; Wang H; Agrawal S; Zhang R
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11636-41. PubMed ID: 13130078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells.
    Yang HL; Dong YB; Elliott MJ; Liu TJ; Atienza C; Stilwell A; McMasters KM
    Clin Cancer Res; 1999 Aug; 5(8):2242-50. PubMed ID: 10473112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 protein overexpression inhibits apoptosis of TF-1 granulocyte-macrophage colony-stimulating factor-dependent acute myeloblastic leukemia cells.
    Urashima M; Teoh G; Chauhan D; Ogata A; Shirahama S; Kaihara C; Matsuzaki M; Matsushima H; Akiyama M; Yuza Y; Maekawa K; Anderson KC
    Blood; 1998 Aug; 92(3):959-67. PubMed ID: 9680365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene.
    Meye A; Würl P; Bache M; Bartel F; Grünbaum U; Mansa-ard J; Schmidt H; Taubert H
    Cancer Lett; 2000 Feb; 149(1-2):181-8. PubMed ID: 10737722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfection with mdm2-antisense or wtp53 results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line.
    Grünbaum U; Meye A; Bache M; Bartel F; Würl P; Schmidt H; Dunst J; Taubert H
    Anticancer Res; 2001; 21(3B):2065-71. PubMed ID: 11497299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mdm2 proto-oncogene sensitizes human medullary thyroid carcinoma cells to ionizing radiation.
    Dilla T; Romero J; Sanstisteban P; Velasco JA
    Oncogene; 2002 Apr; 21(15):2376-86. PubMed ID: 11948421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides.
    Capoulade C; Mir LM; Carlier K; Lécluse Y; Tétaud C; Mishal Z; Wiels J
    Blood; 2001 Feb; 97(4):1043-9. PubMed ID: 11159535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein.
    Urashima M; Ogata A; Chauhan D; Vidriales MB; Teoh G; Hoshi Y; Schlossman RL; DeCaprio JA; Anderson KC
    Blood; 1996 Sep; 88(6):2219-27. PubMed ID: 8822942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
    Mu Z; Hachem P; Agrawal S; Pollack A
    Prostate; 2004 Aug; 60(3):187-96. PubMed ID: 15176048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer.
    Tortora G; Caputo R; Damiano V; Bianco R; Chen J; Agrawal S; Bianco AR; Ciardiello F
    Int J Cancer; 2000 Dec; 88(5):804-9. PubMed ID: 11072252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M; Berberich SJ
    Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mdm2 proto-oncogene.
    Haines DS
    Leuk Lymphoma; 1997 Jul; 26(3-4):227-38. PubMed ID: 9322885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
    Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
    Piovesan B; Pennell N; Berinstein NL
    Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting effect of murine double minute-2 oncogene on apoptosis induced by retroviral-mediated wild-type p53.
    Guo H; Liu T; Gao J
    Chin Med J (Engl); 1998 Dec; 111(12):1102-6. PubMed ID: 11263374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
    Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
    Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.